Efficacy of Sofosbuvir and Ledipasvir in Comparison to Sofosbuvir and Daclatasvir in Management of Egyptian Chronic Hepatitis C Patients
Afro-Egypt. j. infect. enem. dis
;
10(2): 163-173, 2022. tables, figures
Artículo
en Inglés
| AIM
| ID: biblio-1426649
ABSTRACT
In Egypt, the prevalence of hepatitis C virus (HCV) antibodies is the highest worldwide by 7.6%. Applying efficient treatment protocol on large scale could decrease HCV prevalence as well as disease burden.The aim of this study is to compare the efficacy of Sofosbuvir plus ledipasvir versus Sofosbuvir plus daclatasvir in management of chronic hepatitis C Egyptian patients with either easy to treat (naive patients with Child score A5)or difficult to treat (interferon experienced).
Texto completo:
Disponible
Índice:
AIM (África)
Asunto principal:
Resultado del Tratamiento
/
Hepatitis C Crónica
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio observacional
/
Factores de riesgo
Límite:
Humanos
Idioma:
Inglés
Revista:
Afro-Egypt. j. infect. enem. dis
Año:
2022
Tipo del documento:
Artículo
Institución/País de afiliación:
2 Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty f o of Medicine for Girls, AL-Azhar/EG
/
Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty f o of Medicine for Girls/EG
/
Tropical Medicine Department , National Hepatology and Tropical Medicine R R Research Institute/EG
Similares
MEDLINE
...
LILACS
LIS